Research programme: gamma delta T-cell immunotherapy - Gadeta

Drug Profile

Research programme: gamma delta T-cell immunotherapy - Gadeta

Alternative Names: TEG 001

Latest Information Update: 04 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University Medical Center Utrecht
  • Developer Gadeta
  • Class CAR-T cell therapies; Cell therapies; Immunotherapies
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 25 Jul 2017 Gadeta plans a phase I trial of TEG 001 for Acute myeloid leukaemia, Multiple myeloma, Myelodysplastic syndrome (Second-line therapy or greater) in the Netherlands (NTR6541)
  • 29 Mar 2016 Early research in Cancer in Netherlands (Parenteral)
  • 29 Mar 2016 Gadeta plans a phase I trial for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top